Patent · US Active

Recombinant human-basic fibroblast growth factor (rh-bFGF) and pharmaceutical composition comprising rh-bFGF

US11254723B2 · kind B2 · utility

0Cited by

0References

5Claims

0Family size

Assignee

Zhuhai Essex Bio-Pharmaceutical Co., Ltd. · CN

Inventors

Haizhou Fang · Tangxia, CN
Peimin Dai · Tangxia, CN
Bo Yang · Zhejiang, CN
Xinzhi Wang · Tangxia, CN
Zhenheng Wang · Tangxia, CN
Malcolm Ngiam · Hong Kong, CN
Qi Xue · Nanjing, CN
Yingluo Xiong · Tangxia, CN

Key dates

Filing date	Jun 23, 2017
Grant date	Feb 22, 2022
Priority date	—
Expiry date	Jun 23, 2037

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K47/38
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided are a mutated nucleic acid molecule of a recombinant human-basic fibroblast growth factor (rh-bFGF), a pharmaceutical composition of the rh-bFGF, and a use thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.